Abrysvo clinical trials
Also written PF-06928316.
How each study uses abrysvo is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the abrysvo studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
19 studies that test it; most in 2026 (6)
| Year | Studies |
|---|---|
| 2020 | 2 |
| 2021 | 1 |
| 2023 | 3 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 4
Pfizer (14) · Tor Biering-Sørensen (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Hvivo (1) · University of British Columbia (1) · PENTA Foundation (1)
Often tested with
Tested in the same studies.
Nirsevimab (2) · Influenza Vaccines (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4, 3 in phase 3
Studies that test abrysvo, phase 3 first.
- Jan 2027Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.Phase 3 · Pfizer
- Jan 2027A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreFPhase 3 · Pfizer
- May 2027A Study to Learn About the Safety and Immune Responses of RSVpreF in Older AdultsPhase 3 · Pfizer
- Sep 2027Study of HIV-Exposed Pregnancies and Transplacental Antibody Delivery Following RSVpreFPhase 4 · University of British Columbia
Studies
Open first, then newest update. How each study uses abrysvo is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 19
- Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV DiseaseRecruitingPhase 3PfizerNCT07839871Written as RSVpreF
- A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single DoseRecruitingPhase 3PfizerNCT06866405Written as RSVpreF
- A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised AdultsRecruitingPhase 3PfizerNCT07768345Written as RSVpreF Vaccine
- A Study to Learn About the Safety and Immune Responses of RSVpreF in Older AdultsRecruitingPhase 3PfizerNCT07819097Written as RSVpreF
- A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreFRecruitingPhase 3PfizerNCT07653100Written as RSVpreF
- Study of HIV-Exposed Pregnancies and Transplacental Antibody Delivery Following RSVpreFNot yet recruitingPhase 4University of British ColumbiaNCT07693166Written as RSVpreF
- Pregnancy and Infant PrEparedness pLatform IN Europe, RSV-International Adaptive Platform Trial to Evaluate Two Approved Prevention Options to Prevent Respiratory Syncytial Virus in Infants: Maternal Vaccine to Women in Pregnancy and Monoclonal Antibody to the Infants, Given Alone or in Combination.Not yet recruitingPhase 3PENTA FoundationNCT07041190Written as Abrysvo
- A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.CompletedPhase 3PfizerNCT07543380Written as RSVpreF
- A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their InfantsCompletedPhase 3PfizerNCT06325657Written as RSVpreF vaccine
- Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing RSV Hospitalizations in AdultsActive, not recruitingPhase 4Tor Biering-SørensenNCT06684743Written as RSV prefusion F protein-based vaccine
- The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both ProductsCompletedPhase 4National Institute of Allergy and Infectious Diseases (NIAID)NCT06551506Written as Abrysvo
- A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in KoreaCompletedPhase 3PfizerNCT06593587Written as RSVpreF Vaccine
- Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.Active, not recruitingPhase 3PfizerNCT05035212Written as RSVpreF
- A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in AdultsCompletedPhase 3PfizerNCT06890416Written as RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE
- A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV DiseaseCompletedPhase 3PfizerNCT05842967Written as RSVpreF
- A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.CompletedPhase 3PfizerNCT04424316Written as RSVpreF
- A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).CompletedPhase 2PfizerNCT05886777Written as RSVpreF
- A Study to Examine Respiratory Combination Vaccines Against Respiratory Syncytial Virus (RSV) and Flu in Older AdultsCompletedPhase 1PfizerNCT05788237Written as RSVpreF
- Study of RSVpreF Vaccination and RSV Challenge in Healthy AdultsCompletedPhase 2HvivoNCT04785612Written as RSVPreF
Given beside what is tested · 3 — abrysvo is usual care or a partner of the new treatment
- Vaccine Responses in Patients With B Cell MalignanciesRecruitingPhase 4National Heart, Lung, and Blood Institute (NHLBI)NCT05170399Written as AREXVY, ABRYSVO
- Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV VaccinationRecruitingPhase 3Centre Hospitalier Annecy GenevoisNCT07232706Written as Abrysvo
- Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of AgeCompletedPhase 3PfizerNCT05301322Written as RSVpreF Vaccine
As the comparator · 1 — what is tested is compared with abrysvo
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Codes
What other systems call abrysvo · ClinicalTrials.gg INT002038
- MeSH (NLM) C000729228abrysvoOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000729228 | abrysvo | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.